Reported 2 days ago
ImmunoPrecise Antibodies Ltd. has made a significant breakthrough with its LENSai platform, achieving high accuracy in epitope mapping through the use of its proprietary HYFT technology. A benchmark study demonstrated LENSai's capability to predict antibody binding sites on previously unseen targets with impressive accuracy, mirroring results from its training data. This innovative approach enables rapid analysis using just digital sequences, in stark contrast to traditional methods that are time-consuming and resource-heavy. The company is actively expanding partnerships with major pharma and biotech firms, highlighting its potential in the biotech industry.
Source: YAHOO